Jeff Yass’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.66M | Sell |
17,397
-1,411
| -8% | -$171K | ﹤0.01% | 5873 |
|
|
2026
Q1 | $2.34M | Buy |
+18,808
| New | +$1.96M | ﹤0.01% | 5798 |
|
|
2025
Q4 | – | Sell |
-8,008
| Closed | -$683K | – | 13957 |
|
|
2025
Q3 | $502K | Sell |
8,008
-9,376
| -54% | -$418K | ﹤0.01% | 8938 |
|
|
2025
Q2 | $392K | Sell |
17,384
-97,004
| -85% | -$2.28M | ﹤0.01% | 9741 |
|
|
2025
Q1 | $3.2M | Buy |
+114,388
| New | +$2.2M | ﹤0.01% | 4528 |
|
|
2024
Q1 | – | Sell |
-1,287
| Closed | -$18.7K | – | 13580 |
|
|
2023
Q4 | $18.7K | Buy |
+1,287
| New | +$23.6K | ﹤0.01% | 11986 |
|
|
2023
Q2 | – | Sell |
-199
| Closed | -$15.5K | – | 13340 |
|
|
2023
Q1 | $15.5K | Buy |
+199
| New | +$23K | ﹤0.01% | 12110 |
|
|
2022
Q3 | – | Sell |
-421
| Closed | -$54.3K | – | 14290 |
|
|
2022
Q2 | $63K | Sell |
421
-4,211
| -91% | -$768K | ﹤0.01% | 11837 |
|
|
2022
Q1 | $1.12M | Sell |
4,632
-334
| -7% | -$87.8K | ﹤0.01% | 6827 |
|
|
2021
Q4 | $1.5M | Sell |
4,966
-845
| -15% | -$271K | ﹤0.01% | 6207 |
|
|
2021
Q3 | $2.4M | Buy |
5,811
+3,544
| +156% | +$1.23M | ﹤0.01% | 5447 |
|
|
2021
Q2 | $694K | Buy |
+2,267
| New | +$497K | ﹤0.01% | 8764 |
|
|
2021
Q1 | – | Sell |
-297
| Closed | -$59K | – | 12948 |
|
|
2020
Q4 | $59K | Buy |
297
+153
| +106% | +$31.8K | ﹤0.01% | 10708 |
|
|
2020
Q3 | $24K | Buy |
144
+16
| +13% | +$3.64K | ﹤0.01% | 10363 |
|
|
2020
Q2 | $32K | Sell |
128
-181
| -59% | -$42.3K | ﹤0.01% | 9857 |
|
|
2020
Q1 | $56K | Buy |
309
+52
| +20% | +$13.1K | ﹤0.01% | 9633 |
|
|
2019
Q4 | $74K | Sell |
257
-486
| -65% | -$135K | ﹤0.01% | 9240 |
|
|
2019
Q3 | $203K | Buy |
743
+186
| +33% | +$72K | ﹤0.01% | 9072 |
|
|
2019
Q2 | $209K | Buy |
+557
| New | +$166K | ﹤0.01% | 9055 |
|
|
2019
Q1 | – | Sell |
-718
| Closed | -$153K | – | 10004 |
|
|
2018
Q4 | $153K | Sell |
718
-211
| -23% | -$65.5K | ﹤0.01% | 7967 |
|
|
2018
Q3 | $416K | Sell |
929
-280
| -23% | -$122K | ﹤0.01% | 6867 |
|
|
2018
Q2 | $490K | Sell |
1,209
-238
| -16% | -$113K | ﹤0.01% | 6827 |
|
|
2018
Q1 | $790K | Buy |
1,447
+1,018
| +237% | +$630K | ﹤0.01% | 5721 |
|
|
2017
Q4 | $259K | Buy |
+429
| New | +$199K | ﹤0.01% | 7831 |
|
|
2015
Q3 | – | Sell |
-1,617
| Closed | -$356K | – | 10306 |
|
|
2015
Q2 | $356K | Buy |
+1,617
| New | +$356K | ﹤0.01% | 8252 |
|
Other funds holding PVLA
SCM
FLSM
FLAM
BI
FCM
Jeff Yass's PVLA Position: Q2 2026 in Review
Jeff Yass reduced its Palvella Therapeutics (PVLA) stake by 7.5% in Q2 2026, selling an estimated $171K and leaving 17,397 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #5873.
Jeff Yass first reported a position in PVLA in Q2 2015 and has held it in 25 quarters since. The position peaked at $3.2M in Q1 2025. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.
- Jeff Yass held 17,397 shares of Palvella Therapeutics worth $2.66M as of Q2 2026.
- Jeff Yass sold 1,411 Palvella Therapeutics shares in Q2 2026, an estimated $171K.
- Palvella Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5873 holding.
- Jeff Yass first reported a position in Palvella Therapeutics in Q2 2015 and has held it in 25 quarters since.
- Jeff Yass's Palvella Therapeutics position peaked at $3.2M in Q1 2025.
- 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.